House dust mite allergy vaccine - HAL Allergy

Drug Profile

House dust mite allergy vaccine - HAL Allergy

Alternative Names: Purethal Mites

Latest Information Update: 16 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HAL Allergy
  • Class Allergens; Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis; Allergic rhinoconjunctivitis

Most Recent Events

  • 12 Aug 2016 Phase-III clinical trials in Allergic rhinoconjunctivitis and Allergic rhinitis in Hungary (SC) (EudraCT2016-000051-27)
  • 04 Aug 2016 Phase-III clinical trials in Allergic rhinitis and Allergic rhinoconjunctivitis in Belgium (SC) (EudraCT2016-000051-27)
  • 28 Jul 2015 House dust mite allergy vaccine is still in active development in Austria, Belgium, Netherlands and Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top